Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for reversal of neuromuscular blockade in frail elderly patients
ChiCTR2500103503Phase 4Not yet recruiting
- Sponsor
- Kunshan Traditional Chinese Medicine Hospital
- Start
- May 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in neuromuscular block (NMB) (2 arms), sponsored by Kunshan Traditional Chinese Medicine Hospital. Primary endpoints: Residual muscle relaxation rate, Incidence of hypoxemia and 3 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR2500103503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103503.